
|Videos|June 26, 2015
Pembrolizumab in Urothelial Cancer
Author(s)Elizabeth Plimack, MD, MS
Elizabeth Plimack, MD, MS, attending physician, genitourinary cancer associate professor, Medical Oncology Director of Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a study that examined pembrolizumab in patients with urothelial cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
3
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
4
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
5































